Speculative 8-month target - $33.00 MSB for GVHD, COVID ARDS, page-9

  1. 1,101 Posts.
    lightbulb Created with Sketch. 1130
    I noticed you also don't assume initial 100% market share any more, which is a much better approach. People can take these numbers and risk them to their own liking to get a share price guide.

    Have you looked at MSB's ability to supply the number of doses in these numbers in 2021 and 2022? I guess production would be a limiting factor. There's also increasing expenses with increasing revenue (all businesses have cost of revenue) for example sales agent commissions, delivery of supply, marketing expenses, salaries of staff as the business expands. You have margin at 60%, I'm just not experienced enough at biotech business expenses to know how accurate that might be.

    Good analysis though!
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$2.41
Change
0.620(34.6%)
Mkt cap ! $3.084B
Open High Low Value Volume
$1.90 $2.48 $1.90 $58.82M 25.68M

Buyers (Bids)

No. Vol. Price($)
3 100915 $2.40
 

Sellers (Offers)

Price($) Vol. No.
$2.41 99 1
View Market Depth
Last trade - 16.12pm 18/07/2025 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.